Sugi Predict

Sugi Predict / Compounds / Valine

Valine

Valine

SCHEMBL2875734

CC(C)C(N)C(=O)O.O=CO

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 2/20 0.79
▸ SLC1A3 P43003 4/20 0.46
▸ SLC1A2 P43004 4/20 0.46
▸ SLC1A1 P43005 4/20 0.46
▸ GABRP O00591 2/20 0.37
▸ GABRD O14764 2/20 0.37
▸ GABRA1 P14867 2/20 0.37
▸ GABRB1 P18505 2/20 0.37
▸ GABRG2 P18507 2/20 0.37
▸ GABRB3 P28472 2/20 0.37
▸ GABRA5 P31644 2/20 0.37
▸ GABRA3 P34903 2/20 0.37
▸ GABRA2 P47869 2/20 0.37
▸ GABRB2 P47870 2/20 0.37
▸ GABRA4 P48169 2/20 0.37
▸ GABRE P78334 2/20 0.37
▸ GABRA6 Q16445 2/20 0.37
▸ GABRG1 Q8N1C3 2/20 0.37
▸ GABRG3 Q99928 2/20 0.37
▸ GABRQ Q9UN88 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL30548418 1.00 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL1729111 0.90 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL29008223 0.90 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL3286146 0.90 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL10725920 0.90 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL8516 0.89 — —
Valine SCHEMBL1813972 0.89 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL2785563 0.89 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL43678 0.89 — —
Valine SCHEMBL288203 0.89 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107286201-A Stable chain Ni (II) complexes of amino acid with fluorescence property and preparation method thereof 昆明学院 2017-10-24 — — CN disclosed
EP-2120965-B1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS INC (US) 2014-11-05 — — EP disclosed
US-8415497-B2 N-halogenated amino compounds and derivatives NOVABAY PHARMACEUTICALS, INC. (US) 2013-04-09 — — US disclosed
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. 2010-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES DCTD, DDC, DAO SLC7A5 365/4885SLC1A3 1857/4885SLC1A2 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.